Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects

This article was originally published in The Pink Sheet Daily

Executive Summary

Transcept's low-dose zolpidem for middle-of-the-night awakenings may need additional studies, including driving tests.
Advertisement

Related Content

Transcept Sees Road To Intermezzo Approval Without More Driving Studies
Transcept Sees Road To Intermezzo Approval Without More Driving Studies
Transcept Aims To Refile Intermezzo Insomnia NDA In Late Q4 With Highway Driving Data
Transcept Aims To Refile Intermezzo Insomnia NDA With Highway Driving Data
Somaxon Sleep Aid Silenor Not Effective, FDA Says
Insomnia Market Snapshot: Generics May Keep Drug Makers Up At Night
Insomnia Market Snapshot: Generics May Keep Drug Makers Up At Night
Sleepless Nights: Sanofi-Aventis Gets "Complete Response" Letter For Insomnia Drug
Transcept Hopes To Sleep Well Thanks To Insomnia Pill Deal With Purdue Pharma
With Reverse Merger Complete, Transcept Looks To Partner Intermezzo

Topics

Advertisement
UsernamePublicRestriction

Register

PS068683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel